The DOI matches its Crossref record; 92 of the 93 references it cites were found in a registry or an index.
Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy
Open accessAbstract
Inhaled corticosteroids (ICSs) are the most effective anti-inflammatory agents available for the treatment of asthma and represent the mainstay of therapy for most patients with the disease. Although these medications are considered safe at low-to-moderate doses, safety concerns with prolonged use of high ICS doses remain; among these concerns is the risk of adrenal suppression (AS). AS is a condition characterized by the inability to produce adequate amounts of the glucocorticoid, cortisol, which is critical during periods of physiological stress. It is a proven, yet under-recognized, complication of most forms of glucocorticoid therapy that can persist for up to 1 year after cessation of corticosteroid treatment. If left unnoticed, AS can lead to significant morbidity and even mortality. More than 60 recent cases of AS have been described in the literature and almost all cases have involved children being treated with ≥500 μg/day of fluticasone.The risk for AS can be minimized through increased awareness and early recognition of at-risk patients, regular patient follow-up to ensure that the lowest effective ICS doses are being utilized to control asthma symptoms, and by choosing an ICS medication with minimal adrenal effects. Screening for AS should be considered in any child with symptoms of AS, children using high ICS doses, or those with a history of prolonged oral corticosteroid use. Cases of AS should be managed in consultation with a pediatric endocrinologist whenever possible. In patients with proven AS, stress steroid dosing during times of illness or surgery is needed to simulate the protective endogenous elevations in cortisol levels that occur with physiological stress.This article provides an overview of current literature on AS as well as practical recommendations for the prevention, screening and management of this serious complication of ICS therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, among all inhaled glucocorticoids fluticasone propionate is most frequently associated with the development of symptomatic glucocorticoid-induced adrenal insufficiency and exogenous Cushing syndrome (100, 104, 107-111).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [108]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several cases of exogenous Cushing syndrome linked to oral and non-oral glucocorticoid formulations in patients using strong CYP3A4 inhibitors have been published (108, 109).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [108]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harrison's Principles of Internal Medicine.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-499_2 · Cited by 12,514
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
British Guideline on the Management of Asthma
British Thoracic Society Scottish Intercollegiate Guidelines Network (2008) · Thorax · doi:10.1136/thx.2008.097741 · Cited by 2,021
A Clinical Index to Define Risk of Asthma in Young Children with Recurrent Wheezing
CASTRO-RODRÍGUEZ, J. A., HOLBERG, C. J., WRIGHT, A. L., & MARTINEZ, F. D. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.4.9912111 · Cited by 1,153
Low-Dose Inhaled Corticosteroids and the Prevention of Death from Asthma
Suissa, S., Ernst, P., Benayoun, S., Baltzan, M., & Cai, B. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430504 · Cited by 1,100
Harrison's Principles of Internal Medicine 16th ed
Badiu, C. (2005) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2005.499 · Cited by 1,021
Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis
Lipworth, B. J. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.9.941 · Cited by 918
Agertoft, L., & Pedersen, S. (1994) · Respiratory Medicine · doi:10.1016/0954-6111(94)90044-2 · Cited by 756
Effect of Long-Term Treatment with Inhaled Budesonide on Adult Height in Children with Asthma
Agertoft, L., & Pedersen, S. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010123431502 · Cited by 576
DICKSTEIN, G., SHECHNER, C., NICHOLSON, W. E., ROSNER, I., SHEN-ORR, Z., ADAWI, F., & LAHAV, M. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-4-773 · Cited by 457
Research works printed but not linked: 4
- Public Health Agency of Canada: Life and breath: respiratory disease in Canada. 2007, Ottawa, Ontario, Available, Accessed July 15, 2010, [ http://www.phac-aspc.gc.ca/publicat/2007/lbrdc-vsmrc/index-eng.php ]
- Bantle J, Ercan-Fang N: The adrenal cortex. Endocrine Pathophysiology. Edited by: Niewoehner C. 2004, Raleigh: Hayes Barton Press, 84-108. 2
- Niewoehner C, (ed): Endocrine Pathophysiology. 2004, Raleigh: Hayes Barton Press, 2
- Donohoue PA: Causes and clinical manifestations of primary adrenal insufficiency in children. Up to Date. 2010, Accessed, April 29, 2011, [ http://www.uptodate.com/contents/causes-and-clinical-manifestations-of-primary-adrenal-insufficiency-in-children?source=search_result&selectedTitle=1%7E51 ]
Cited by
Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E. D., Leigh, R., Brown, J. P., Cohen, A., & Kim, H. (2013) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-9-30 · Cited by 1,268
Self-citationTurner, D., Ruemmele, F. M., Orlanski‐Meyer, E., Griffiths, A. M., de Carpi, J. M., Bronsky, J., Veres, G., Aloi, M., Strisciuglio, C., Braegger, C. P., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002035 · Cited by 481
Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma
Heffler, E., Madeira, L. N. G., Ferrando, M., Puggioni, F., Racca, F., Malvezzi, L., Passalacqua, G., & Canonica, G. W. (2018) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.01.025 · Cited by 233
Glucocorticoid induced adrenal insufficiency
Prete, A., & Bancos, I. (2021) · BMJ · doi:10.1136/bmj.n1380 · Cited by 155
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Metadata
- Authors
- Ahmet, A., Kim, H., & Spier, S.
- Affiliations
- University of Ottawa (CA)
- Western University (CA)
- University of Calgary (CA)
- Corresponding author
- Ahmet, Alexandra
- Venue
- Allergy, Asthma & Clinical Immunology
- Published
- 2011-08-25
- Volume
- 7
- Issue
- 1
- Pages
- 13-13
- ISSN
- 1710-1484 (ISSN-L)
- 1710-1492
- PMC
- PMC3177893
- OpenAlex
- W2119298560
- Cited by
- 114
- References
- 93
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 10 · 2023: 8 · 2022: 4 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 10 · 2017: 4 · 2016: 12 · 2015: 10 · 2014: 8 · 2013: 9 · 2012: 5
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- Allergy Asthma and Clinical Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- uO Research (University of Ottawa) (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- adrenal suppression, inhaled corticosteroids, asthma, fluticasone, glucocorticoid therapy, cortisol, screening, pediatric patients, adrenal insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. https://app.cochat.ai/papers/10.1186/1710-1492-7-13
- The paper
- Ahmet, A., Kim, H., & Spier, S. (2011). Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. Allergy, Asthma & Clinical Immunology. https://doi.org/10.1186/1710-1492-7-13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Figure 1 Schematic representation of the fate of an ICS. [53,58] Adapted from Derendorf et al., 2006 [53]; Derendorf, 1997 [58].](https://figures.cochat.ai/paper-figures/90f375d10d454a1fbaf419edaf87a535/adrenal-suppression-a-practical-guide-to-the-screening-and-management-of-this-figure-1.jpg)